News / Health

New Malaria Drugs Stop Parasite Early

Animal tests promising, but human trials still ahead

US scientists are experimenting with a compound of anti-malaria drugs that kill the parasite in its dormant liver stage.
US scientists are experimenting with a compound of anti-malaria drugs that kill the parasite in its dormant liver stage.

Multimedia

Audio
TEXT SIZE - +
Art Chimes

U.S. medical researchers report a possible breakthrough that might prevent infection by one of the two most widespread varieties of malaria.

A new class of anti-malaria compounds kills the parasites in the developmental stages in the liver, before they get into the bloodstream.

The compounds proved highly successful in animal tests, according to a study published in Science, but their effectiveness in humans is still unproven.

Plasmodium vivax is the dominant strain of the malaria parasite outside Africa. Unlike the more deadly Plasmodium falciparum, vivax can infect a person but stay dormant in the liver for months or even years, before emerging to cause disease.

Scientists at the Scripps Research Institute in California and other institutions evaluated chemical compounds that were known to kill the malaria parasite in the blood. They were looking for ones that also might kill the parasite in its dormant liver stage.

In this study, the researchers mixed each one of the compounds with malaria parasites taken from live mosquitoes. Each combination was put with liver cells into individual compartments, called wells, on a microscope slide. Author Elizabeth Winzeler explains that to screen thousands of chemicals as potential malaria drugs required some sophisticated technology.

"We used an automated microscope to go and take about 100 images of each of the wells, and then we used computer scripts to analyze the images and identify those wells that had compounds that appeared to affect the development of the parasites."

To test potential drugs developed from the chemicals that looked promising, Winzeler and her colleagues infected laboratory mice with the malaria parasite. Left alone, the mice died within 10 days.  But "if you give the mice the same treatment, and you give them a small oral dose of the compounds that we made, the mice are cured or they never develop malaria in the first place."

These new substances, called IZPs, are effective in mice, Winzeler says, "but there's always a big step between going from something that works in a mouse model and actually going into something that's safe and efficacious in humans."

Researchers at Scripps, backed by the pharmaceutical company Novartis, are now considering that next step, safety testing in humans.

If successful, this work could lead to a malaria drug that attacks the dormant stage of the parasite, which occurs only in the Plasmodium vivax form of the disease. Scientists theorize that this period of dormancy was an evolutionary strategy to keep infection active through the cold winter months.

"For example, vivax malaria was found in places like Finland and England, up until about 100 years ago. And clearly, there weren't mosquitoes out biting people in December."

Vivax now occurs mainly in Asia and Latin America.

You May Like

Multimedia Anti-Keystone XL Protests Continue

Demonstrators are worried about pipeline's effect on climate change, their traditional way of life, health and safety More

Thailand's Political Power Struggle Continues

Court gave Prime Minister Yingluck Shinawatra until May 2 to prepare her defense over abuse of power charges but uncertainty remains over election timing More

Malaysia Plane Search Tests Limits of Ocean Mapping Technology

Expert tells VOA existing equipment’s maximum operating depth is around 6 kilometers as operation continues on ocean bed for any trace of MH370 More

This forum has been closed.
Comments
     
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Pet Kangaroo Helps Spread Environmental Messagei
X
Penelope Poulou
April 22, 2014 5:53 PM
Children’s author Julia Heckathorn travels the world to learn about different ecosystems and endangered animals. She pours her knowledge into children’s books, hoping the next generation will right the environmental wrongs of our times. As in many children's books, the main character in Heckathorn's stories is an animal. Unlike those other characters, though, this one is real - a kangaroo, that lives in the author’s backyard. VOA’s Penelope Poulou has more.
Video

Video Pet Kangaroo Helps Spread Environmental Message

Children’s author Julia Heckathorn travels the world to learn about different ecosystems and endangered animals. She pours her knowledge into children’s books, hoping the next generation will right the environmental wrongs of our times. As in many children's books, the main character in Heckathorn's stories is an animal. Unlike those other characters, though, this one is real - a kangaroo, that lives in the author’s backyard. VOA’s Penelope Poulou has more.
Video

Video Pro-Russian Separatists Plan 'Federalization Referendum' in Eastern Ukraine

Pro-Russian separatists in eastern Ukraine say they plan to move forward next month with a referendum vote for greater autonomy, despite the Geneva agreement reached with Russia, the U.S. and Ukraine to end the political conflict. VOA's Brian Padden reports from the city of Donetsk in Eastern Ukraine.
Video

Video Pope Francis Hopes Dual Canonizations Will Reconcile Church

On April 27, two popes - John the XXIII and John Paul II - will be made saints in a ceremony at St. Peter’s Square. VOA religion correspondent Jerome Socolovsky says the dual canonization is part of the current pope’s program to reconcile liberals and conservatives in the Roman Catholic Church.
Video

Video In Capturing Nature's Majesty, Film Makes Case for Its Survival

French filmmaker Luc Jacquet won worldwide acclaim for his 2005 Academy Award-winning documentary "March of the Penguins". Now Jacquet is back with a new film that takes movie-goers deep into the heart of a tropical rainforest - not only to celebrate its grandeur, but to make the case for its survival. VOA's Rosanne Skirble reports.
Video

Video Boston Marathon Bittersweet for Many Runners

Monday's running of the Boston Marathon was bittersweet for many of the 36,000 participants as they finished the run that was interrupted by a double bombing last year. Many gathered along the route paid respect to the four people killed as a result of two bombings near the finish line. VOA's Carolyn Presutti returned to Boston this year to follow two runners, forever changed because of the crimes.
Video

Video International Students Learn Film Production in World's Movie Capital

Hollywood - which is part of Los Angeles - is the movie capital of the world, and many aspiring filmmakers go there in hopes of breaking into the movie business. Mike O'Sullivan reports that regional universities are also a magnet for students who hope to become producers or directors.
Video

Video Pacific Rim Trade Deal Proves Elusive

With the U.S.-led war in Iraq ended and American military involvement in Afghanistan winding down, President Barack Obama has sought to pivot the country's foreign policy focus towards Asia. One aspect of that pivot is the negotiation of a free-trade agreement among 12 Pacific Rim nations. But as Obama leaves this week on a trip to four Asian countries he has found it very difficult to complete the trade pact. VOA's Ken Bredemeier has more from Washington.
Video

Video Autistic Adults Face Housing, Job Challenges

Many parents of children with disabilities fear for the future of their adult child. It can be difficult to find services to help adults with disabilities - physical, mental or emotional - find work or live on their own. The mother of an autistic boy set up a foundation to advocate for the estimated 1.2 million American adults with autism, a developmental disorder that causes communication difficulties and often social difficulties. VOA's Faiza Elmasry reports.
AppleAndroid